Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
Taysha Gene Therapies (NASDAQ:TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, will host its Q2 2025 financial results conference call on August 12, 2025, at 8:30 AM ET. The company will present its financial performance for the quarter ended June 30, 2025, along with a corporate update.
Investors can access the call via toll-free number (877-407-0792) or international line (201-689-8263) using conference ID 13754869. A webcast will also be available on the company's investor relations website.
Taysha Gene Therapies (NASDAQ:TSHA), un'azienda biotecnologica in fase clinica specializzata in terapie geniche basate su AAV per le malattie del sistema nervoso centrale, terrà la sua conference call sui risultati finanziari del secondo trimestre 2025 il 12 agosto 2025 alle 8:30 AM ET. La società presenterà i risultati finanziari del trimestre conclusosi il 30 giugno 2025, insieme a un aggiornamento aziendale.
Gli investitori potranno partecipare alla chiamata tramite numero verde (877-407-0792) o linea internazionale (201-689-8263) utilizzando l'ID conferenza 13754869. Sarà inoltre disponibile una diretta web sul sito dedicato agli investitori della società.
Taysha Gene Therapies (NASDAQ:TSHA), una empresa biotecnológica en fase clínica especializada en terapias génicas basadas en AAV para enfermedades del sistema nervioso central, realizará su conferencia telefónica de resultados financieros del segundo trimestre de 2025 el 12 de agosto de 2025 a las 8:30 AM ET. La compañía presentará su desempeño financiero correspondiente al trimestre finalizado el 30 de junio de 2025, junto con una actualización corporativa.
Los inversores podrán acceder a la llamada mediante número gratuito (877-407-0792) o línea internacional (201-689-8263) usando el ID de conferencia 13754869. También habrá una transmisión en línea disponible en la página web de relaciones con inversionistas de la empresa.
Taysha Gene Therapies (NASDAQ:TSHA)는 중추신경계 질환을 위한 AAV 기반 유전자 치료제를 전문으로 하는 임상 단계 바이오테크 기업으로, 2025년 8월 12일 오전 8시 30분(동부시간)에 2025년 2분기 재무 실적 컨퍼런스 콜을 개최합니다. 회사는 2025년 6월 30일 종료된 분기의 재무 성과와 함께 기업 업데이트를 발표할 예정입니다.
투자자들은 무료 전화번호(877-407-0792) 또는 국제 전화(201-689-8263)를 통해 컨퍼런스 ID 13754869를 사용하여 콜에 참여할 수 있습니다. 또한 회사 투자자 관계 웹사이트에서 웹캐스트도 제공됩니다.
Taysha Gene Therapies (NASDAQ:TSHA), une entreprise biotechnologique en phase clinique spécialisée dans les thérapies géniques à base de vecteurs AAV pour les maladies du système nerveux central, tiendra sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2025 le 12 août 2025 à 8h30 ET. La société présentera ses performances financières pour le trimestre clos au 30 juin 2025, ainsi qu'une mise à jour corporative.
Les investisseurs pourront accéder à l'appel via le numéro vert (877-407-0792) ou la ligne internationale (201-689-8263) en utilisant l'ID de conférence 13754869. Un webcast sera également disponible sur le site des relations investisseurs de la société.
Taysha Gene Therapies (NASDAQ:TSHA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für Erkrankungen des zentralen Nervensystems spezialisiert hat, wird seine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2025 am 12. August 2025 um 8:30 Uhr ET abhalten. Das Unternehmen wird seine finanzielle Leistung für das Quartal zum 30. Juni 2025 sowie ein Unternehmensupdate präsentieren.
Investoren können die Telefonkonferenz über die gebührenfreie Nummer (877-407-0792) oder die internationale Leitung (201-689-8263) mit der Konferenz-ID 13754869 verfolgen. Ein Webcast wird ebenfalls auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, at 8:30 AM Eastern Time.
Conference Call Details
Tuesday, August 12, at 8:30 AM Eastern Time / 7:30 AM Central Time
Toll Free: 877-407-0792
International: 201-689-8263
Conference ID: 13754869
Webcast: https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com
FAQ
When will Taysha Gene Therapies (TSHA) report Q2 2025 earnings?
How can investors access Taysha Gene Therapies' Q2 2025 earnings call?
What is Taysha Gene Therapies' main business focus?
What period will Taysha Gene Therapies' financial results cover?
